MNG1007
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.487
- TGF_BETA_SIGNALING+0.466
- ANDROGEN_RESPONSE+0.329
- HEME_METABOLISM+0.310
- FATTY_ACID_METABOLISM+0.260
- ADIPOGENESIS+0.255
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.252
- NOTCH_SIGNALING+0.243
- DNA_REPAIR+0.233
- MYC_TARGETS_V1+0.229
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.442
- ALLOGRAFT_REJECTION-0.334
- E2F_TARGETS-0.277
- MYC_TARGETS_V2-0.266
- ANGIOGENESIS-0.234
- KRAS_SIGNALING_DN-0.202
- MYOGENESIS-0.199
- G2M_CHECKPOINT-0.178
- COAGULATION-0.166
- INTERFERON_GAMMA_RESPONSE-0.153
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1214 | — | — | 0.887 |
| 2 | MNG1024 | — | — | 0.886 |
| 3 | MNG1034 | — | — | 0.836 |
| 4 | MNG995 | — | — | 0.806 |
| 5 | MNG1051 | — | — | 0.790 |
| 6 | MNG579 | — | — | 0.777 |
| 7 | SRR6013523 | — | cohortA1 | 0.775 |
| 8 | R319 | — | — | 0.765 |
| 9 | TCGA-BH-A0BS-01A-11R-A12P-07 | — | B | 0.763 |
| 10 | TCGA-44-6146-01A-11R-A278-07 | — | cohortA1 | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.487 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.466 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.329 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.310 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.255 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.252 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.243 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.233 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.229 | Inavolisib | — uncovered |
| APOPTOSIS | 0.183 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.171 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.164 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.154 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.148 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.148 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.121 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.121 | Idelalisib | — uncovered |